Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05324098 · ClinicalTrials.gov registry record · NA

Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy

A NA study of Prostate Cancer, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
47
Enrollment target
2
Study locations

NCT05324098: Completed NA study of Prostate Cancer, sponsored by University of California, San Francisco.

NCT05324098 is a NA study of Prostate Cancer that has completed, run by University of California, San Francisco. The registered enrollment target is 47 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05324098, a NA study of Prostate Cancer, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target
2
Study locations

Study Summary

This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostate cancer. STAND-T is a digital platform that provides prostate health information, evidence-based materials and resources. STAND-T may help improve health, address symptoms, and promote equity in men with prostate cancer.

Primary Outcome

The point estimation and 95% confidence interval (CI) of the percentage of participants who complete the 3-month study will be obtained overall and by race/ethnicity and geography.

Conditions Studied

Interventions

  • OTHER Survey Administration
  • OTHER STAND-T platform
  • OTHER Text Messages

Study Locations (2)

California

  • Zuckerberg San Francisco General Hospital - San Francisco
  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2022-03-08
Est. Completion 2023-07-31
Phase NA

What the finished NCT05324098 record still lists

NCT05324098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.

NCT05324098 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05324098 about?

NCT05324098 is a clinical study titled "Leveraging Technology to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy". This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostate cancer. STAND-T is a digital platform that provides prostate health information, evidence-based ma...

What is the current status of trial NCT05324098?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2022-03-08. Estimated completion is 2023-07-31.

What conditions does trial NCT05324098 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT05324098?

The interventions under investigation include: Survey Administration (OTHER), STAND-T platform (OTHER), Text Messages (OTHER).

Who is sponsoring clinical trial NCT05324098?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05324098 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05324098's enrollment target sits among peer trials

47 502nd of 735 higher than 233 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03313011 · 47 participants

    The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

  • NCT03467516 · 47 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

  • NCT03886662 · 47 participants · Phase 1

    A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

  • NCT04013802 · 47 participants · Phase 1

    TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05324098, the US trial registry maintained by the National Library of Medicine. NCT05324098 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.